Salus Bioceutical Thailand establishes first state-of-the-art, high-capacity cannabis/hemp manufacturing and extraction laboratory in Asia in response to surging demand for CBD and THC products

Salus Bioceutical Thailand establishes the first laboratory for the manufacture and extraction of hemp and the latest generation of hemp in Asia in response to the growing demand for CBD and THC products

Bangkok, Thailand, December 22, 2021 – Salus Bioceutical (Thailand) Co. Ltd. (SBT), in collaboration with Salus International Management Ltd. (SIM), a wholly owned subsidiary of MPX International Corporation (MPXI), a diversified multinational cannabis company, is opening a 600 million baht cannabis and hemp production plant (“the facility”) in the district of Doi Saket in Chiang Mai Province, Thailand. The facility will initially produce CBD products to meet growing international and local demand, so THC products and medicines will be developed subject to government approval in accordance with applicable laws.

The world-class facility is expected to have an annual capacity for the extraction of more than 200,000 kilos of biomass and the production of more than 50,000 liters of CBD oil and 90,000 kilograms of powdered and isolated. Water-soluble CBD, making SBT one of the largest. Cannabis and hemp manufacturing plants in Thailand and the most sophisticated production site outside of North America. The 800 m2 plant covers indoor cultivation and an additional building, high-capacity extraction and distillation capacity that employs some of the most technologically advanced equipment available in the cannabis industry, as well as a medical-grade laboratory for hemp and cannabis analysis, which will allow for a single analysis. distillation process, ultimately producing high-performance, high-quality CBD products that stand out from competitors. With the experience of MPXI, an emerging global cannabis industry participant operating on five continents, SBT will implement best-in-class manufacturing practices at its GMP-compliant medical production facilities in Thailand and the UK. EU-GMP. SBT has recently received a hemp extraction license, which allows SBT to operate and extract hemp flower legally under Thai law, making it one of the first companies in Thailand with full licenses for the manufacture of hemp. CBD.

W. Scott Boyes, President and CEO of MPXI and President and President of SIM, said: “The emerging market for medical grade CBD and THC products in Thailand is maturing rapidly and the Thai government’s progressive approach can make this country possible.the epicenter of medicinal cannabis cultivation and production for all of Southeast Asia.MPXI is pleased to play a comprehensive role in the planning, development and management of the Chiang facility. As a shareholder and participant in the company, MPXI expects the project to provide short-term revenue and profits that materially support the financial performance of MPXI and SIM, as well as providing a significant advantage to MPXI and SIM shareholders. .

Amid the global wave of cannabis, Thailand, with a population of over 70 million, is a promising national jurisdiction for the industry after the legal use of medical cannabis in 2019. It is estimated that there there are about 600,000 Thai patients who can be treated with cannabis and as Thailand is currently the third most visited country by medical tourists in the world, the integration of cannabis into the medical tourism industry alone is expected to bring in $ 60 million by 2024. Medical professionals are also encouraging medical cannabis to be considered a cultural heritage. aspect of Thailand.

Tanadee Pantumkomon, CEO and CEO of SBT, said: “We are excited to take our first big step in Thailand. Opening our local CBD manufacturing plant will allow us to better respond to the growing demand for a wide range of variety of CBD products both in Thailand and around the world. The facility will create an upstream and downstream value chain and provide benefits for all stakeholders, including job opportunities and additional income for local communities. ” .

SBT will work closely with the Cannabis & Herbs Institute of Rajamangala Isan University of Technology, where institutional research will be conducted to understand the agriculture and agronomy of cannabis and hemp plants in the tropics, as well as extraction for medical purposes such as a forerunner of various industrial sectors. In addition, SBT also aims to participate in the development of communities and local farmers in outdoor cultivation operations and in hemp biomass greenhouse high in CBD and low in THC. SBT has built demonstration sites for outdoor hemp cultivation on five different campuses of Rajamangala Isan Technological University to develop cultivation techniques and pass on the knowledge to local farmers.

As Thailand continues to venture into the medical cannabis market, several opportunities for future business will open up. As the first U.S. medical cannabis company to enter the Thai market, SBT will initially produce EU-GMP-compliant medical grade cannabis products, such as CBD distillate, powder isolated and water-soluble CBD isolate for to domestic sales. The company will focus on producing high quality products for the domestic market and aims to dominate the ASEAN community by expanding sales throughout the Southeast Asian region. With Thailand declaring itself an exporting country, export potential can be estimated at $ 618 million by 2024.

As we move forward with a strong customer base and customer support, SBT will expand into various market segments. Having received interest from various food and beverage, cosmetics, healthcare, supplements, massage and spa and feed manufacturers based in Thailand, SBT will potentially produce distilled / isolated CBD for commercial use during the fourth quarter of 2021. In the pharmaceutical field, SBT is in the process of qualifying the facility for GMP quality medical cannabis and, subject to government approval, will produce sublingual tablets and capsules, suppositories, transdermal patches and edibles. of medical quality containing other cannabinoids beneficial to health.